GGrantIndex
← Leaderboards

Shyam S Mohapatra

James A. Haley Va Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$5,225,407
Attributed
$7,749,537
Total exposure
17
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.3M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,749,537 · 9
VA$0 · 8

By mechanism

R01$5,706,448 · 4
P30$1,329,000 · 1
R21$436,173 · 1
R41$267,916 · 2
R13$10,000 · 1
IK6$0 · 2

Top collaborators

Most similar at James A. Haley Va Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Mouse Model”

Research focus

Mouse ModelInnovationCellsLeadBaseRespiratory Syncytial VirusPeptidesLungPharmaceutical PreparationsCollaborationsIn VivoIn VitroClinical TrialsReportingPrevent3-DimensionalRespiratory Syncytial Virus InfectionsInflammationFutureMesenchymal Stem CellsEpithelial CellsNanomedicineProgramsSmall Interfering Rna

Grant awards (51)

Molecular Targets Modulating Neuro COVID Sequelae Linked to Tauopathy$734,995
R01 · FY2025 · AG
Treatment of lupus nephritis with nanoparticles that selectively target kidney glomeruli$567,139
R01 · FY2025 · DK
Anti-inflammatory and hMSC combination therapy for traumatic brain injury$0
I01 · FY2025 · VA
Nanoformulations for Respiratory Infections$0
I01 · FY2025 · VA · contact PI
BLRD Merit Review Research Career Scientist Award$0
IK6 · FY2025 · VA · contact PI
Molecular Targets Modulating Neuro COVID Sequelae Linked to Tauopathy$749,994
R01 · FY2024 · AG
Treatment of lupus nephritis with nanoparticles that selectively target kidney glomeruli$544,453
R01 · FY2024 · DK
BLRD Merit Review Research Career Scientist Award$0
IK6 · FY2024 · VA · contact PI
Anti-inflammatory and hMSC combination therapy for traumatic brain injury$0
I01 · FY2024 · VA
Treatment of lupus nephritis with nanoparticles that selectively target kidney glomeruli$579,208
R01 · FY2023 · DK
BLRD Merit Review Research Career Scientist Award$0
IK6 · FY2023 · VA · contact PI
COVID-19: SARS-CoV-2 Neutralizing Agents$0
I01 · FY2023 · VA
Anti-inflammatory and hMSC combination therapy for traumatic brain injury$0
I01 · FY2023 · VA
Tumor targeted engineered stem cells for treatment of lung cancer$0
I01 · FY2022 · VA
Nanomicellar antiviral strategies for RSV infection$0
I01 · FY2022 · VA · contact PI
BLRD Merit Review Research Career Scientist Award$0
IK6 · FY2022 · VA · contact PI
COVID-19: SARS-CoV-2 Neutralizing Agents$0
I01 · FY2022 · VA
COVID-19: SARS-CoV-2 Neutralizing Agents$0
I01 · FY2021 · VA
BLRD Research Career Scientist Award Application$0
IK6 · FY2021 · VA · contact PI
Tumor targeted engineered stem cells for treatment of lung cancer$0
I01 · FY2021 · VA
BLRD Research Career Scientist Award Application$0
IK6 · FY2020 · VA · contact PI
Nanomicellar antiviral strategies for RSV infection$0
I01 · FY2020 · VA · contact PI
Tumor targeted engineered stem cells for treatment of lung cancer$0
I01 · FY2020 · VA
Tumor targeted engineered stem cells for treatment of lung cancer$0
I01 · FY2019 · VA
BLRD Research Career Scientist Award Application$0
IK6 · FY2019 · VA · contact PI
Nanomicellar antiviral strategies for RSV infection$0
I01 · FY2019 · VA · contact PI
Nanomicellar antiviral strategies for RSV infection$0
I01 · FY2018 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2018 · VA · contact PI
Tumor targeted engineered stem cells for treatment of lung cancer$0
I01 · FY2018 · VA
Nanomicellar antiviral strategies for RSV infection$0
I01 · FY2017 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2017 · VA · contact PI
Development of Nanotherapeutics for RSV-induced Lung Disease$0
I01 · FY2015 · VA · contact PI
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers$286,998
R01 · FY2014 · CA · contact PI
Development of Nanotherapeutics for RSV-induced Lung Disease$0
I01 · FY2014 · VA · contact PI
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers$193,703
R01 · FY2013 · CA · contact PI
Development of Nanotherapeutics for RSV-induced Lung Disease$0
I01 · FY2013 · VA · contact PI
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers$295,874
R01 · FY2012 · CA · contact PI
Development of Nanotherapeutics for RSV-induced Lung Disease$0
I01 · FY2012 · VA · contact PI
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers$295,874
R01 · FY2011 · CA · contact PI
Conference: Advances in Translational Research in AIDS/HIV in INDIA$10,000
R13 · FY2011 · AI · contact PI
Nanomedicine Research Center Core (NRCC)$664,500
P30 · FY2010 · HL · contact PI
An Integrated Nano-Cell Delivery Platform of Theranostics for Lung Cancers$305,025
R01 · FY2010 · CA · contact PI
Nanomedicine Research Center Core (NRCC)$664,500
P30 · FY2009 · HL · contact PI
Association between ANP and NPRA Gene Polymorphisms and Severity of Atopy and Ast$236,813
R21 · FY2009 · HL · contact PI
Association between ANP and NPRA Gene Polymorphisms and Severity of Atopy and Ast$199,360
R21 · FY2008 · HL · contact PI
Chitosan IFNgamma-pDNA Nanosphere Therapy and Immunopathology of Allergic Asthma$283,185
R01 · FY2006 · HL · contact PI
Chitosan IFNgamma-pDNA Nanosphere Therapy and Immunopathology of Allergic Asthma$290,000
R01 · FY2005 · HL
Chitosan IFNgamma-pDNA Nanosphere Therapy and Immunopathology of Allergic Asthma$290,000
R01 · FY2004 · HL
Chlipoplex Nanoparticle Prophylactics for RSV Infection$157,893
R41 · FY2004 · HL
Chliposome IFN-gamma-pDNA Naoparticle Therapy for Asthma$110,023
R41 · FY2004 · HL
Chitosan IFNgamma-pDNA Nanosphere Therapy and Immunopathology of Allergic Asthma$290,000
R01 · FY2003 · HL